A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).

臺大醫院;臺大醫學院-臨床醫學研究所;Yau, Thomas CheungThomas CheungYauSukeepaisarnjaroen, WattanaWattanaSukeepaisarnjaroenChao, YeeYeeChaoYen, Chia-JuiChia-JuiYenLausoontornsiri, WiroteWiroteLausoontornsiriChen, Pei-JerPei-JerChenSanpajit, TheeranunTheeranunSanpajitLencioni, RiccardoRiccardoLencioniCamp, Aaron C.Aaron C.CampCox, Donna S.Donna S.CoxKallender, HowardHowardKallenderOttesen, Lone HarildLone HarildOttesenPoon, Ronnie Tung-PingRonnie Tung-PingPoon2017-06-222018-07-062017-06-222018-07-062012http://ntur.lib.ntu.edu.tw//handle/246246/279558A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC).